Recent Updates
Recently added Catalysts
CORT Positive Sentiment

Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)

Thursday, June 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10) presented findings on the efficacy and safety of Relacorilant combined with Nab-paclitaxel in treating platinum-resistant ovarian cancer in patients aged 65 and older. The results were shared at the European Society for Medical Oncology Gynaecological Cancers Annual Congress. The study's focus on older patients addresses a significant gap in treatment options.
Price reaction · baseline $80.88 (2026-06-18T15:59:00.000Z) · hit during market hours · 1 other CORT headline(s) in the window, move may be shared
day 0 close · peak
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Efficacy of Relacorilant + Nab-paclitaxel shows promise in treatment.
  • Study focuses on a critical patient demographic aged 65 and older.
  • Presentation at a reputable congress highlights the significance of the findings.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+283%
120-day peak, hindsight
Typical move
4.8%
average across 6 past catalysts
Lead asset
mifepristone+ fluvastatin
Phase 1 · Healthy Subjects

Full Press Release Details

Presented : European Society for Medical Oncology Gynaecological Cancers Annual C o ngress , 18 June 2026, Copenhagen, DK
Presenter : Domenica Lorusso , MD , PhD
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Poster
The post Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10) appeared first on Corcept Therapeutics .

Frequently Asked Questions

What is the ROSELLA Study about?

The ROSELLA Study investigates the efficacy and safety of Relacorilant combined with Nab-paclitaxel in older patients with platinum-resistant ovarian cancer.

Who presented the findings of the study?

The findings were presented by Domenica Lorusso, MD, PhD, at a medical congress.

What age group does the study focus on?

The study focuses on patients aged 65 years and older.

Where was the study presented?

The study was presented at the European Society for Medical Oncology Gynaecological Cancers Annual Congress in Copenhagen.

ShareAdd on Google
Tags: CORT Viatris Investor Conferences Healthcare Relacorilant Nab-paclitaxel ovarian cancer platinum-resistant
Last updated: Jun 18, 2026

Biotech snapshot

Cash runway
$545M liquidity · $0M/mo burn
Low dilution risk
Lead asset
mifepristone+ fluvastatinPhase 1
Healthy Subjects →

Catalyst track record

+283%
best trade around CORT's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CORT.

See every catalyst's timing & PoA →